Gene Expression Profiling in Multiple Myeloma: Redefining the Paradigm of Risk-Adapted Treatment

Overview

Journal Front Oncol

Specialty Oncology

Date 2022 Feb 25

PMID 35211412

Authors

Claudio Cerchione

Saad Z Usmani

A Keith Stewart

Martin Kaiser

Leo Rasche

Martin Kortum

Maria-Victoria Mateos

Andrew Spencer

Pieter Sonneveld

Kenneth C Anderson

Affiliations

Soon will be listed here.

Abstract

Multiple myeloma is a blood cancer characterized by clonal proliferation of plasma cells in the bone marrow. In recent years, several new drugs have been added to the therapeutic landscape of multiple myeloma, which have contributed to increased survival rates. However, while the use of therapeutics has evolved, there is still a group of high-risk patients who do not benefit from current treatment strategies. Risk stratification and risk-adapted treatment are crucial to identify the group of patients with urgent need for novel therapies. Gene expression profiling has been introduced as a tool for risk stratification in multiple myeloma based on the genetic make-up of myeloma cells. In this review we discuss the challenge of defining the high-risk multiple myeloma patient. We focus on the standardized analysis of myeloma cancer cells by gene expression profiling and describe how gene expression profiling provides additional insights for optimal risk-adapted treatment of patients suffering from multiple myeloma.

Citing Articles

Plasma Cell Neoplasms with Spreading in the Blood and Tissues: Extramedullary Myeloma Disease, a Rare Aggressive Form of Multiple Myeloma (First of Two Parts).

Testa U, Leone G Mediterr J Hematol Infect Dis. 2025; 17(1):e2025005.

PMID: 39830797 PMC: 11740910. DOI: 10.4084/MJHID.2025.005.

Characterization of driver mutations identifies gene signatures predictive of prognosis and treatment sensitivity in multiple myeloma.

Li J, Parthasarathy A, Kannappan A, Arsang-Jang S, Dong J, Cheng C Oncologist. 2024; 29(11):e1552-e1564.

PMID: 39250742 PMC: 11639189. DOI: 10.1093/oncolo/oyae244.

Exploring the molecular biomarker utility of circCCT3 in multiple myeloma: A favorable prognostic indicator, particularly for R-ISS II patients.

Papatsirou M, Kontos C, Ntanasis-Stathopoulos I, Malandrakis P, Sideris D, Fotiou D Hemasphere. 2024; 8(1):e34.

PMID: 38434522 PMC: 10878196. DOI: 10.1002/hem3.34.

Variability of definition of high-risk multiple myeloma across phase III clinical trials.

Abu Zanouneh F, Ababneh O, Schinke C, Thanendrarajan S, Zangari M, Shaughnessy Jr J EJHaem. 2023; 4(2):454-458.

PMID: 37206288 PMC: 10188470. DOI: 10.1002/jha2.675.

An early post-transplant relapse prediction score in multiple myeloma: a large cohort study from the chronic malignancies working party of EBMT.

Beksac M, Iacobelli S, Koster L, Cornelissen J, Griskevicius L, Rabin N Bone Marrow Transplant. 2023; 58(8):916-923.

PMID: 37160942 DOI: 10.1038/s41409-023-01999-1.

References

Greipp P, San Miguel J, Durie B, Crowley J, Barlogie B, Blade J . International staging system for multiple myeloma. J Clin Oncol. 2005; 23(15):3412-20. DOI: 10.1200/JCO.2005.04.242. View

Biran N, Dhakal B, Lentzsch S, Siegel D, Usmani S, Rossi A . Gene expression profiling impacts treatment decision making in newly diagnosed multiple myeloma patients in the prospective PROMMIS trial. EJHaem. 2022; 2(3):375-384. PMC: 9175784. DOI: 10.1002/jha2.209. View

Smadja N, Bastard C, Brigaudeau C, Leroux D, Fruchart C . Hypodiploidy is a major prognostic factor in multiple myeloma. Blood. 2001; 98(7):2229-38. DOI: 10.1182/blood.v98.7.2229. View

Dewald G, Therneau T, Larson D, Lee Y, Fink S, Smoley S . Relationship of patient survival and chromosome anomalies detected in metaphase and/or interphase cells at diagnosis of myeloma. Blood. 2005; 106(10):3553-8. PMC: 1895058. DOI: 10.1182/blood-2005-05-1981. View

Shaughnessy Jr J, Zhan F, Burington B, Huang Y, Colla S, Hanamura I . A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. Blood. 2006; 109(6):2276-84. DOI: 10.1182/blood-2006-07-038430. View

Durie B, Salmon S . A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer. 1975; 36(3):842-54. DOI: 10.1002/1097-0142(197509)36:3<842::aid-cncr2820360303>3.0.co;2-u. View

Sonneveld P, Avet-Loiseau H, Lonial S, Usmani S, Siegel D, Anderson K . Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group. Blood. 2016; 127(24):2955-62. PMC: 4920674. DOI: 10.1182/blood-2016-01-631200. View

Barlogie B, Bolejack V, Schell M, Crowley J . Prognostic factor analyses of myeloma survival with intergroup trial S9321 (INT 0141): examining whether different variables govern different time segments of survival. Ann Hematol. 2010; 90(4):423-8. PMC: 3053415. DOI: 10.1007/s00277-010-1130-y. View

Kin K, Kasahara T, Itoh Y, Sakurabayashi I, Kawai T, Morita M . beta2-Microglobulin production by highly purified human T and B lymphocytes in cell culture stimulated with various mitogens. Immunology. 1979; 36(1):47-54. PMC: 1457399. View

10.

. Multiple myeloma: 2018 update on diagnosis, risk‐stratification, and management. Am J Hematol. 2018; 93(8):981-1114. PMC: 6223128. DOI: 10.1002/ajh.25117. View

11.

Pawlyn C, Cairns D, Kaiser M, Striha A, Jones J, Shah V . The relative importance of factors predicting outcome for myeloma patients at different ages: results from 3894 patients in the Myeloma XI trial. Leukemia. 2019; 34(2):604-612. PMC: 7214257. DOI: 10.1038/s41375-019-0595-5. View

12.

Mihou D, Katodritou I, Zervas K . Evaluation of five staging systems in 470 patients with multiple myeloma. Haematologica. 2006; 91(8):1149-50. View

13.

Gertz M, Lacy M, Dispenzieri A, Greipp P, Litzow M, Henderson K . Clinical implications of t(11;14)(q13;q32), t(4;14)(p16.3;q32), and -17p13 in myeloma patients treated with high-dose therapy. Blood. 2005; 106(8):2837-40. PMC: 1895302. DOI: 10.1182/blood-2005-04-1411. View

14.

Anagnostopoulos A, Gika D, Symeonidis A, Zervas K, Pouli A, Repoussis P . Multiple myeloma in elderly patients: prognostic factors and outcome. Eur J Haematol. 2005; 75(5):370-5. DOI: 10.1111/j.1600-0609.2005.00532.x. View

15.

Terpos E, Katodritou E, Roussou M, Pouli A, Michalis E, Delimpasi S . High serum lactate dehydrogenase adds prognostic value to the international myeloma staging system even in the era of novel agents. Eur J Haematol. 2010; 85(2):114-9. DOI: 10.1111/j.1600-0609.2010.01466.x. View

16.

Kumar S, Rajkumar S, Dispenzieri A, Lacy M, Hayman S, Buadi F . Improved survival in multiple myeloma and the impact of novel therapies. Blood. 2007; 111(5):2516-20. PMC: 2254544. DOI: 10.1182/blood-2007-10-116129. View

17.

Kuiper R, Broyl A, de Knegt Y, van Vliet M, van Beers E, van der Holt B . A gene expression signature for high-risk multiple myeloma. Leukemia. 2012; 26(11):2406-13. DOI: 10.1038/leu.2012.127. View

18.

Avet-Loiseau H . Ultra high-risk myeloma. Hematology Am Soc Hematol Educ Program. 2011; 2010:489-93. DOI: 10.1182/asheducation-2010.1.489. View

19.

Child J, Crawford S, Norfolk D, OQuigley J, Scarffe J, Struthers L . Evaluation of serum beta 2-microglobulin as a prognostic indicator in myelomatosis. Br J Cancer. 1983; 47(1):111-4. PMC: 2011252. DOI: 10.1038/bjc.1983.13. View

20.

Chang H, Qi X, Jiang A, Xu W, Young T, Reece D . 1p21 deletions are strongly associated with 1q21 gains and are an independent adverse prognostic factor for the outcome of high-dose chemotherapy in patients with multiple myeloma. Bone Marrow Transplant. 2009; 45(1):117-21. DOI: 10.1038/bmt.2009.107. View